iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Aurobindo Pharma-led arm bags USFDA Approval for Vasopressin Injection USP; stock under pressure

16 Aug 2022 , 10:59 AM

Aurobindo Pharma Limited announced that its wholly-owned subsidiary company, Eugia Pharma Specialties Limited, has secured the final approval from the US Food & Drug Administration (USFDA) for manufacturing and marketing Vasopressin Injection USP, 20 Units/mL Multiple-Dose Vials.

The company stated that Vasopressin Injection USP, 20 Units/mL Multiple-Dose Vials, are to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vasostrict Injection, 20 units/mL of Par Sterile Products, LLC (Par).

The company is planning to launch the product immediately.

As per the IQVIA data, the product has an estimated market size of around US$ 606 million for the twelve months ended June 2022.

This is the 146 ANDA (including ten tentative approvals) received by Eugia Pharma Speciality Group (EPSG) facilities, which manufacture both oral and sterile specialty products.

Vasopressin USP Injection is prescribed to treat Cardiovascular agent: vasoconstrictor. It is indicated to raise blood pressure in adults suffering from vasodilatory shock (for example, post-cardiotomy or sepsis).

At around 11.03 AM, Aurobindo Pharma was trading at Rs590.70 down by Rs2.6 or 0.44% from its previous closing of Rs593.30 on the BSE. The scrip opened at Rs594 and touched intraday high and low of Rs602.75 and Rs589.30 respectively.

Related Tags

  • Aurobindo Pharma New Drug
  • Aurobindo Pharma News
  • Aurobindo Pharma Stocks
  • Aurobindo Pharma Updates
  • Eugia Pharma
  • Eugia Pharma News
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.